Lineage Cell Therapeutics, Inc. (LCTX)
| Market Cap | 413.98M |
| Revenue (ttm) | 2.71M |
| Net Income (ttm) | -27.16M |
| Shares Out | 149.97M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $2.67 |
| Previous Close | $2.76 |
| Change ($) | -0.09 |
| Change (%) | -3.26% |
| Day's Open | 2.84 |
| Day's Range | 2.61 - 2.85 |
| Day's Volume | 1,339,895 |
| 52-Week Range | 0.60 - 3.00 |
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies fo...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies fo...
Investors need to pay close attention to Lineage Cell Therapeutics (LCTX) stock based on the movements in the options market lately.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies f...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies fo...
Lineage Cell Therapeutics, Inc. is a clinical-stage biotech company focused on developing therapeutics for degenerative retinal diseases, demyelination-related neurological conditions, and can...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #DryAMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapie...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies f...
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2020 Results - Earnings Call Transcript
Lineage Cell (LCTX) delivered earnings and revenue surprises of 20.00% and -12.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unm...
CARLSBAD, Calif. & LONDON--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapie...
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.
CARLSBAD, Calif. & ALAMEDA, Calif.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q2 2020 Results - Earnings Call Transcript
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #AMD--Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Is A High-Risk But High-Reward Opportunity To Consider
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q1 2020 Results - Earnings Call Transcript
Is (LCTX) Outperforming Other Medical Stocks This Year?
On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline...
As of late, it has definitely been a great time to be an investor Lineage Cell Therapeutics
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lineage Cell Therapeutics, Inc. (LCTX) has been struggling lately, but the selling pressure may be coming to an end soon.
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2019 Results - Earnings Call Transcript
Lineage Cell (LCTX) delivered earnings and revenue surprises of 57.14% and 108.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTime, Inc. (LCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q3 2019 Results - Earnings Call Transcript
Lineage Cell Therapeutics has suffered a marked decreasing trend in recent years.
About LCTX
Lineage Cell Therapeutics, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal c... [Read more...]
| Industry Biotechnology | Founded 1990 |
| CEO Brian Culley | Employees 50 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol LCTX |
Financial Performance
In 2019, LCTX's revenue was $3.52 million, a decrease of -29.53% compared to the previous year's $4.99 million. Losses were -$11.71 million, -74.54% less than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is 4.80, which is an increase of 79.78% from the latest price.